{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:15:46Z","timestamp":1783707346135,"version":"3.55.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"\n We examined whether COVID-19 vaccine type was associated with national full-vaccination coverage using 1034 country\u2013vaccine entries from 195 countries derived from World Health Organization data. In a country-level analysis adjusting for World Bank income group, WHO region, and the number of vaccine products per country, neither mRNA vaccine availability (\n p<\/jats:italic>\n \u2009=\u20090.051) nor the proportion of mRNA vaccines in a country\u2019s portfolio (\n p<\/jats:italic>\n \u2009=\u20090.164) was significantly associated with coverage. Vaccine-related variables added only one percentage point to the explained variance beyond structural factors (\n \n \n \n \n \n \u0394<\/mml:mo>\n \n R<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 0.011<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ). Unadjusted exploratory analyses showed that some vaccine products were more frequently recorded in high-coverage country contexts, but these patterns were substantially attenuated after adjustment for structural covariates. The apparent link between vaccine category and coverage largely reflected differences in economic capacity, geographic region, and deployment context rather than vaccine category itself.\n <\/jats:p>","DOI":"10.1371\/journal.pgph.0006682","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:50:28Z","timestamp":1783705828000},"page":"e0006682","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-national patterns of COVID-19 vaccination coverage by vaccine type"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-5617","authenticated-orcid":true,"given":"Walid","family":"Al-Zyoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Erekat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-4961","authenticated-orcid":true,"given":"Mohammad","family":"Abudayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"pgph.0006682.ref001","unstructured":"Mayo Clinic. Different types of COVID-19 vaccines: how they work. [cited 2025 Dec 30]. https:\/\/www.mayoclinic.org\/diseases-conditions\/coronavirus\/in-depth\/different-types-of-covid-19-vaccines\/art-20506465"},{"key":"pgph.0006682.ref002","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Gavrilov D, Giattino C, et al. COVID-19 pandemic. Our World in Data. 2020. https:\/\/ourworldindata.org\/coronavirus"},{"issue":"10278","key":"pgph.0006682.ref003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"OJ Wouters","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"pgph.0006682.ref004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","article-title":"A global survey of potential acceptance of a COVID-19 vaccine","volume":"27","author":"JV Lazarus","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"pgph.0006682.ref005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines9020160","article-title":"COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates","volume":"9","author":"M Sallam","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"pgph.0006682.ref006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25594","article-title":"Factors associated with US adults\u2019 likelihood of accepting COVID-19 vaccination","volume":"3","author":"S Kreps","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10255","key":"pgph.0006682.ref007","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"A de Figueiredo","year":"2020","journal-title":"Lancet"},{"key":"pgph.0006682.ref008","article-title":"Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust","author":"K Thiagarajan","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"pgph.0006682.ref009","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10900-020-00958-x","article-title":"COVID-19 vaccination hesitancy in the United States: a rapid national assessment","volume":"46","author":"J Khubchandani","year":"2021","journal-title":"J Community Health"},{"issue":"27","key":"pgph.0006682.ref010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"pgph.0006682.ref011","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10269","key":"pgph.0006682.ref012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"10296","key":"pgph.0006682.ref013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"MD Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"pgph.0006682.ref014","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"N Dagan","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pgph.0006682.ref015","article-title":"Covid-19: How effective are vaccines against the delta variant?","author":"C Baraniuk","year":"2021","journal-title":"BMJ"},{"key":"pgph.0006682.ref016","unstructured":"World Health Organization. COVID-19 cases \u2014 WHO COVID-19 dashboard. [cited 2025 Nov 5]. https:\/\/data.who.int\/dashboards\/covid19\/cases"},{"issue":"1","key":"pgph.0006682.ref017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1037\/1082-989X.7.1.19","article-title":"On the practice of dichotomization of quantitative variables","volume":"7","author":"RC MacCallum","year":"2002","journal-title":"Psychol Methods"},{"key":"pgph.0006682.ref018","unstructured":"World Bank. World Bank country and lending groups. [cited 2026 April 14]. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"issue":"2","key":"pgph.0006682.ref019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.11613\/BM.2013.018","article-title":"The chi-square test of independence","volume":"23","author":"ML McHugh","year":"2013","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"pgph.0006682.ref020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3368\/jhr.50.2.317","article-title":"A practitioner\u2019s guide to cluster-robust inference","volume":"50","author":"A Colin Cameron","year":"2015","journal-title":"J Human Resources"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:50:33Z","timestamp":1783705833000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006682"}},"subtitle":[],"editor":[{"given":"Ting","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0006682","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}